



**PATIENT**

Sumo Marks

**SPECIES**

Canine

**BREED**

Japanese Chin

**SEX**

Male Neutered

**AGE**

years

**WEIGHT**

18.1lbs

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

**IMAGING PERFORMED BY**

Renee Trionfetti, VMD

**HOSPITAL NAME**

Cypress Veterinary  
Clinic

**REFERRING VET**

Dr. Johnson

**INVOICE**

47329

**DATE**

3/26/26

**PRESENTING CLINICAL SIGNS**

History: Recheck echo. Grade 3-4/6 heart murmur. On Pimobendan 1.5mg BID.

BP: 129, 129mmHg. Labs: WNL. Sedated with Gabapentin and Trazadone.

-Pertinent previous echo findings (10/2025 MML): CVD B2. Moderate MR, moderate LAE, mild LVE, trace TR. LA: 2.0, LV: 3.7.

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets (anterior>posterior) with mild prolapse into the left atrial lumen. Severe eccentric mitral regurgitation with moderate left atrial dilation. Normal MR velocity. Mildly increased LV diameter with hyperdynamic myocardial function. The tricuspid valve appears subjectively normal, with trace tricuspid regurgitation. Normal velocity. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. Mild aortic and no pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed. Hypochoic lesion cranial to the heart base, consistent with a cyst.

**CARDIAC CHART**

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
<b>NORMAL PARAMETER</b>	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
<b>PATIENT</b>	5.8	2.7	NM	1.8	50	82	0.2
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
<b>NORMAL PARAMETER</b>	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
<b>PATIENT</b>	160	1.5	1.4	8.2	2.0	3.5	1.7
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

**INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Compared to the prior study, findings are persistently stable. The MR is increased quantitatively; however, the left heart dimensions are unchanged. Trace TR persists without obvious pulmonary hypertension. Finally, the previously noted cyst remains apparent.



## PATIENT

Sumo Marks

## SPECIES

Canine

## BREED

Japanese Chin

## SEX

Male Neutered

## AGE

years

## WEIGHT

18.1lbs

## INTERPRETED BY

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

## IMAGING PERFORMED BY

Renee Trionfetti, VMD

## HOSPITAL NAME

Cypress Veterinary  
Clinic

## REFERRING VET

Dr. Johnson

## INVOICE

47329

## DATE

3/26/26

Given these findings, continue Pimobendan going forward. Prognosis remains guarded long-term, as previously discussed. Patient may be at risk for development of CHF, arrhythmias, and/or sudden death going forward.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.


Anesthetic risk remains mildly elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

## PLAN

Baseline BP recommended every 6 months. Continue Pimobendan 0.25-0.3mg/kg PO q12h. Consider Hydrocodone if needed.

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any

## IMAGES



**The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.**

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

**Maggie Machen Lamy, DVM**  
**Diplomate of the American College of Veterinary Internal Medicine (Cardiology)**  
info@sonopath.com



## PATIENT

Sumo Marks

## SPECIES

Canine

## BREED

Japanese Chin

## SEX

Male Neutered

## AGE

years

## WEIGHT

18.1lbs

## INTERPRETED BY

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

## IMAGING PERFORMED BY

Renee Trionfetti, VMD

## HOSPITAL NAME

Cypress Veterinary  
Clinic

## REFERRING VET

Dr. Johnson

## INVOICE

47329

## DATE

3/26/26